NCT06848946 Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
| NCT ID | NCT06848946 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Glaukos Corporation |
| Condition | Glaucoma, Open-angle |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 132 participants in total. It began in 2025-01-13 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
Eligibility Criteria
Inclusion Criteria: * Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye. * OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery) Exclusion Criteria: * Active corneal inflammation or edema. * Retinal disorders not associated with glaucoma.
Contact & Investigator
Study Director
STUDY CHAIR
Glaukos Corporation
Frequently Asked Questions
Who can join the NCT06848946 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Glaucoma, Open-angle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06848946 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06848946 currently recruiting?
Yes, NCT06848946 is actively recruiting participants. Contact the research team at ClinicalResearch@glaukos.com for enrollment information.
Where is the NCT06848946 trial being conducted?
This trial is being conducted at Kenosha, United States.
Who is sponsoring the NCT06848946 clinical trial?
NCT06848946 is sponsored by Glaukos Corporation. The principal investigator is Study Director at Glaukos Corporation. The trial plans to enroll 132 participants.